Poultry Pharmaceuticals Market Size is valued at USD 6.72 Bn in 2022 and is predicted to reach USD 14.03 Bn by the year 2031 at an 8.68% CAGR during the forecast period for 2023-2031.
Poultry pharmaceuticals, referred to as poultry medications or veterinary drugs for poultry, encompass a range of pharmaceutical treatments specifically formulated to promote the health and overall welfare of poultry, including chickens, turkeys, ducks, and other domestic fowl. The poultry pharmaceutical sector has a significant impact on the healthcare system worldwide, from patients in need of medication to doctors interested in cutting-edge research. Keeping up with the latest developments in the market is essential if you want to succeed. Poultry pharmaceutical businesses increase the birds' immune systems so that they manufacture antibodies much more quickly to fight off invaders, hence halting the spread of a particular disease. Vaccines for chickens are critical for preventing illness outbreaks. Vaccine development efforts have primarily focused on fighting viral infections in poultry. Vaccines can be administered by the nares, oral cavity, eyes, skin, or musculature.
In addition, the number of medicines that have been licensed for use and the necessity for poultry vaccinations to cure diseases are expected to propel market expansion over the forecast period. A poultry farm's profitability and productivity are directly correlated to the quality of the birds' health care.
However, the use of poultry vaccines has a wide range of consequences: mild discharge from the eyes and nose, local swelling and discomfort at the vaccination site, a loss of appetite and energy, sneezing, a mild temperature, and a minor cough are all symptoms that may occur locally. Thus, this aspect challenges the expansion of the market. The spread of COVID-19 has considerably impacted the demand for poultry healthcare.
Animal items like meat, milk, and eggs had trouble making it to needs in the beginning because of the disruption in the supply chain caused by the international embargo. As the number of reported instances of COVID-19 has decreased, trade and agricultural output have increased, leading to better care and nutrition for the hens, which has raised the need for poultry healthcare, propelling the market forward throughout the projection period. The increasing prevalence of zoonotic infections, together with the increased demand for poultry-derived food products, are all factors that are driving market expansion.
The poultry pharmaceutical market is segmented based on product type, feed additives and animal type. As per the product type, the market is segmented into drugs, verotoxin, other drug products, vaccines, INNOVAX, NOBILIS, poulvac, and other vaccine products. By feed additives the market is segmented into VIGOSINE, Amnovit, and other feed additives. By animal type, the market is segmented into chicken, turkey, duck, goose, and others.
The drugs category is expected to hold a major global market share in 2022. The rising incidence of Zoonotic diseases is driving growth in the drug segment of the poultry pharmaceuticals market over the forecast period. To protect the health and wellbeing of the birds, to prevent the emergence of antibiotic resistance, and to address other potential problems, it is crucial for poultry farmers and veterinarians to administer these medications sensibly and in line with the law.
Chicken is projected to grow rapidly in the global poultry pharmaceuticals market. Due to this, chicken is predicted to be the most lucrative sub-segment of the global poultry pharmaceuticals market over the forecast period. Growth in this sector is anticipated during the projection period to be driven by the increased government measures to preventative vaccines in countries like the US, Germany, the UK, China, and India.
The North American poultry pharmaceuticals Market is expected to record the maximum market share in revenue in the near future. It can be attributed to increased demand in the global poultry pharmaceuticals market, which may be traced back to the rising incidence of Zoonotic and infectious diseases. In addition, Asia Pacific is estimated to grow rapidly because more people are learning about the importance of preventing diseases like polio and rabies. The government is providing free inoculation camps to protect more people from contagious diseases.
| Report Attribute | Specifications |
| Market Size Value In 2022 | USD 6.72 Bn |
| Revenue Forecast In 2031 | USD 14.03 Bn |
| Growth Rate CAGR | CAGR of 8.68% from 2023 to 2031 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
| Historic Year | 2019 to 2022 |
| Forecast Year | 2023-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Product Type, Animal Type |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia |
| Competitive Landscape | Aervoe Industries Inc., Bayer AG, Bimeda, Ceva Sante Animale, Elanco Animal Health (Eli Lilly and Company), Merck Animal Health, Merial Animal Health (Sanofi), Virbac, Boehringer Ingelheim, Zoetis, Inc., Pacific GeneTech, Avivagen Inc., Hester Biosciences Limited, Venkys India, Calier, KM Biologics, Others |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Poultry Pharmaceuticals Market By product type -
Poultry Pharmaceuticals Market By Animal Type -
Poultry Pharmaceuticals Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.